Openbookopenbook
Equity
Kyowa Kirin Co., Ltd.(KYKOY)
USD --+0.00%
Reward53Moderate
Risk30Moderate
📊75%Data
2.5% dividend yield · Revenue growing 11% YoY
KYKOY
+0.0 · +0.00%
USD · OTCGREY
Kyowa Kirin Co., Ltd. | Healthcare
Defensive Anchor
Market Cap:9.59Bn
ℹ️
Reward Rating
53
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
30
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on KYKOY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Kyowa Kirin Co., Ltd.?

engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide.

KYKOY · Verdict

Moderate reward · low risk

KYKOY leads on volatility with the rest of the factors in line with peers.

Based on 88% data coverage

KYKOY · Verdict

What’s working & what to watch

Strengths 1

  • Volatility95/100

    Top decile vs peers

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Kyowa Kirin Co., Ltd.?

engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachromatic leukodystrophy; Orkedia for treatment of secondary hyperparathyroidism; and Romiplate to treat aplastic anemia. The company is listed on the OTCGREY in USA, operating in the Healthcare sector, with a market capitalisation of 9.59B, and a P/E ratio of 19.7x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (53)

The scoring profile indicates limited reward potential at this time, with profitability and growth offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap9.59B
P/E Ratio19.7349
Dividend Yield2.46%
52 Week High19.8
52 Week Low14.1769
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding523M
No. of Employees5,669
IndustryDrug Manufacturers - Specialty & Generic
ExchangeOTCGREY
Beta0.006
CurrencyUSD · Reports in JPY
Websitewww.kyowakirin.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.